Form 4 for TWST Twist Bioscience Corp
Accepted 2022-02-09 00:00:00 ET · period of report 2022-02-07 · accession 0001214659-22-002109 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-09 | 2022-02-07 | TWST | Mai Xiaoying | Dir | A - Grant | $0.00 | +13.5K | 13.5K | New | $0 |
| DM | 2022-02-09 | 2022-02-07 | TWST | Mai Xiaoying | Dir | A - Grant | $0.00 | +22.9K | 11.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-07 | A | A | 13,539 | $0.00 | 13,539 | D | — | — | (F1) Each equity is fully vested at the time of grant, but represent equity awards for prior annual meetings in 2019, 2020 and 2021 that the Company was not able to grant. If the grants had been made at the time of the prior annual meetings, each grant would have vested upon the earlier of (1) the 1 year anniversary of the date of grant or (2) the next annual meeting. |
| 2 | Derivative | Director Stock Option (right to buy) | 2022-02-07 | A | A | 10,588 | $0.00 | 10,588 | D | $60.33 · — to 2029-07-22 | 10,588 Common Stock | (F1) Each equity is fully vested at the time of grant, but represent equity awards for prior annual meetings in 2019, 2020 and 2021 that the Company was not able to grant. If the grants had been made at the time of the prior annual meetings, each grant would have vested upon the earlier of (1) the 1 year anniversary of the date of grant or (2) the next annual meeting. |
| 3 | Derivative | Director Stock Option (right to buy) | 2022-02-07 | A | A | 973 | $0.00 | 973 | D | $189.96 · — to 2031-02-02 | 973 Common Stock | (F1) Each equity is fully vested at the time of grant, but represent equity awards for prior annual meetings in 2019, 2020 and 2021 that the Company was not able to grant. If the grants had been made at the time of the prior annual meetings, each grant would have vested upon the earlier of (1) the 1 year anniversary of the date of grant or (2) the next annual meeting. |
| 4 | Derivative | Director Stock Option (right to buy) | 2022-02-07 | A | A | 11,297 | $0.00 | 11,297 | D | $60.33 · — to 2030-02-03 | 11,297 Common Stock | (F1) Each equity is fully vested at the time of grant, but represent equity awards for prior annual meetings in 2019, 2020 and 2021 that the Company was not able to grant. If the grants had been made at the time of the prior annual meetings, each grant would have vested upon the earlier of (1) the 1 year anniversary of the date of grant or (2) the next annual meeting. |